Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case
Abu Dhabi’s push to become a global life-sciences hub has
Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?
With a $130m Series B, the startup is betting that
When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials
Regulators have just qualified an AI system to score liver
The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech
Lila’s Nvidia-backed raise is about more than money. It is
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
How AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant Bacteria
Antibiotic resistance poses a significant global health threat, rendering many
Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies
CircNova, a Michigan-based biotechnology startup, has successfully raised $3.3 million
Unlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug Discovery
Abstract This report explores the transformative impact of generative artificial
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
MOST POPULAR
